BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Noyan S, Andac Ozketen A, Gurdal H, Gur Dedeoglu B. miR-770-5p regulates EMT and invasion in TNBC cells by targeting DNMT3A. Cell Signal 2021;83:109996. [PMID: 33798630 DOI: 10.1016/j.cellsig.2021.109996] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Muhammad A, Forcados GE, Katsayal BS, Bako RS, Aminu S, Sadiq IZ, Abubakar MB, Yusuf AP, Malami I, Faruk M, Ibrahim S, Pase PA, Ahmed S, Abubakar IB, Abubakar M, Yates C. Potential epigenetic modifications implicated in triple- to quadruple-negative breast cancer transition: a review. Epigenomics 2022. [PMID: 35473304 DOI: 10.2217/epi-2022-0033] [Reference Citation Analysis]
2 He W, Yang G, Liu S, Maghsoudloo M, Shasaltaneh MD, Kaboli PJ, Zhang C, Zhang J, Entezari M, Imani S, Wen Q. Comparative mRNA/micro-RNA co-expression network drives melanomagenesis by promoting epithelial-mesenchymal transition and vasculogenic mimicry signaling. Transl Oncol 2021;14:101237. [PMID: 34626953 DOI: 10.1016/j.tranon.2021.101237] [Reference Citation Analysis]
3 Ma X, Wang J, Hu G, Chen Y, Hu X, Zhu Y, Ding L, Ning S. Sesamol Epigenetically Induces Estrogen Receptor α Re-expression by Upregulating miR-370-3p in Estrogen Receptor α-Negative Breast Cancer. J Agric Food Chem 2021;69:8737-46. [PMID: 34325508 DOI: 10.1021/acs.jafc.1c03159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Guo Q, Pei XH, Chu AJ, Guo YB, Fan YY, Wang CH, Zhang SJ, Sun SQ, Liu YF, Wang X. The mechanism of action of Fangji Huangqi Decoction on epithelial-mesenchymal transition in breast cancer using high-throughput next-generation sequencing and network pharmacology. J Ethnopharmacol 2022;284:114793. [PMID: 34728317 DOI: 10.1016/j.jep.2021.114793] [Reference Citation Analysis]
5 Man X, Li Q, Wang B, Zhang H, Zhang S, Li Z. DNMT3A and DNMT3B in Breast Tumorigenesis and Potential Therapy. Front Cell Dev Biol 2022;10:916725. [PMID: 35620052 DOI: 10.3389/fcell.2022.916725] [Reference Citation Analysis]